Gilead Sciences and partner Arcellx reported pivotal-stage data showing deep and durable responses for anito-cel in multiple myeloma, with a 96% overall response rate and 74% complete remission among 117 patients. The companies said there were no new safety signals in the latest analysis presented at the ASH meeting. Kite Pharma’s leadership signaled preparedness to scale and commercialize the therapy as it positions anito-cel to challenge current multiple-myeloma CAR-T options. The data were released via company statements and ASH abstracts, and executives framed the results as critical for regaining momentum in the blood-cancer CAR-T market. Investors and competing developers will watch durability, manufacturing throughput, and real-world safety as key determinants of whether anito-cel can expand CAR-T use beyond specialized centers.